Hemoglobin A1c Testing Market to Spike to $1.6 Billion by 2017

Tuesday 16 April 2013, Amsterdam

The newly published “Hemoglobin A1c Testing Markets” report that the hemoglobin A1c testing market will spike to $1.6 billion by 2017.

Hemoglobin A1c testing can be categorized into three main modalities: clinical laboratory HbA1c testing, point of care HbA1c testing and physician office laboratories (POL) HbA1c testing. The POC segment occupies nearly one third of the total hemoglobin A1c testing market and is one of the fastest growing areas, with a CAGR of 12.7% between 2012 and 2017. The U.S. hemoglobin A1c testing market is projected to grow to $518 million in 2017. Combined, the developed regions comprise greater than 75% of the total hemoglobin A1c testing market.

The “Hemoglobin A1c Testing Markets” report covers:

• Diabetes
• Pre-Diabetes Syndrome
• Metabolic Syndrome
• High-Performance Liquid Chromatography (HPLC)
• Immunoassays
• Boronate Affinity Chromatography
• Enzymatic Assay
• Micro-Optical Detection Methods
• Diabetes Control and Complications Trial (DCCT)
• National Glycohemoglobin Standardization Program (NGSP)
• International Federation of Clinical Chemistry (IFCC)
• A1c Derived Average Glucose (ADAG)

    
The “Hemoglobin A1c Testing Markets” report examines companies manufacturing hemoglobin A1c testing equipment and supplies in the world.

Companies covered include:

• A. Menarini,
•  Abbott,
• Alere,
• Arkray,
• Axis-Shield,
• Bayer Healthcare,
• Beckman Coulter,
• Bio-Rad,
• EKF,
• Infopia,
• Ortho Clinical,
• Quotient,
• Randox,
• Roche,
• Siemens,
• Tosoh and Trinity.